转移性去势抵抗性前列腺癌(mCRPC)是一种恶性程度高的晚期前列腺肿瘤，其致死率高、治疗难度高，困扰着全世界的男性患者和医生。免疫治疗是近年来mCRPC治疗的研究热点，本文将从免疫治疗的理论基础到临床治疗应用，全面地介绍其现在的发展与未来的展望。“,”Metastatic castration-resistant prostate cancer (mCRPC) is a kind of highly malignant advanced prostate carcinoma, whose high fatality rate and low cure rate bother the worldwide male patients and doctors. In the last few years, immunotherapy has become an important cancer treatment modality. This article reviews the recent progress and future direction of the modern immunotherapy from the theoretical basis to clinical application.